Jan 31, 2025 · Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14. Axsome focuses on CNS conditions including depression, Alzheimer's disease …

1 day ago · NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the …

1 day ago · In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full …

5 days ago · Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. …

Jan 31, 2025 · Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo.

Nov 27, 2024 · Axsome now plans to move “expeditiously” toward an FDA filing, but it will first request a pre-new drug application meeting with the agency, the executive added.

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the …

1 day ago · “Axsome is proud of its commitment to innovating treatments aimed at improving the lives of the millions of patients living with central nervous system disorders.

2 days ago · Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a …

2 days ago · Dive Brief: Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent settlement with Teva …